BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB

Rushworth, Stuart A., Bowles, Kristian M. ORCID: https://orcid.org/0000-0003-1334-4526, Barrera, Lawrence N., Murray, Megan Y., Zaitseva, Lyubov and MacEwan, David J. (2013) BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-κB. Cellular Signalling, 25 (1). pp. 106-112.

Full text not available from this repository. (Request a copy)

Abstract

Ibrutinib (previously known as PCI-32765) has recently shown encouraging clinical activity in chronic lymphocytic leukaemia (CLL) effecting cell death through inhibition of Bruton's tyrosine kinase (BTK). In this study we report for the first time that ibrutinib is cytotoxic to malignant plasma cells from patients with multiple myeloma (MM) and furthermore that treatment with ibrutinib significantly augments the cytotoxic activity of bortezomib and lenalidomide chemotherapies. We describe that the cytotoxicity of ibrutinib in MM is mediated via an inhibitory effect on the nuclear factor-κB (NF-κB) pathway. Specifically, ibrutinib blocks the phosphorylation of serine-536 of the p65 subunit of NF-κB, preventing its nuclear translocation, resulting in down-regulation of anti-apoptotic proteins Bcl-xL, FLIPL and survivin and culminating in caspase-mediated apoptosis within the malignant plasma cells. Taken together these data provide a platform for clinical trials of ibrutinib in myeloma and a rationale for its use in combination therapy, particularly with bortezomib.

Item Type:	Article
Faculty \ School:	Faculty of Science > School of Pharmacy Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Users 2731 not found.
Date Deposited:	18 Jan 2013 13:22
Last Modified:	25 Oct 2023 00:33
URI:	https://ueaeprints.uea.ac.uk/id/eprint/40855
DOI:	10.1016/j.cellsig.2012.09.008

Actions (login required)

View Item